Hat mitgewirkt an:
-
Tofacitinib (Xeljanz) : der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa
-
DNA-Protein-Interaktionen
-
Animal Models of Inflammatory Bowel Diseases: Illuminating the Pathogenesis of Colitis, Ileitis and Cancer
-
Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges